CD Biosynsis offers advanced Sf9 Cells-Based Assay and Modeling Services, integrating cutting-edge experimental analysis with powerful computational modeling to facilitate rational cell line and bioprocess optimization for the Baculovirus Expression Vector System (BEVS). Sf9 cells (derived from Spodoptera frugiperda) are key hosts for producing complex recombinant proteins, VLPs (Virus-Like Particles), and vaccine antigens, requiring accurate folding and PTMs. Our services move beyond empirical methods by providing a deep, quantitative understanding of the host's behavior under viral stress. We combine high-precision In Vitro and In Vivo assays (metabolomics, proteomics, glycan analysis) with Constraint-Based Metabolic Modeling (CBM) and Dynamic Kinetic Modeling to accurately predict metabolic flux, optimize gene expression timing, and pinpoint systemic bottlenecks within the Sf9/BEVS system. This integrated approach minimizes trial-and-error, ensuring rapid and predictable development of high-performance Sf9 cell lines for commercial biomanufacturing.
Get a QuoteOptimizing the Sf9/BEVS system requires managing the metabolic demands and stress imposed by the viral infection and high-level protein expression, particularly the limited time window before cell lysis. Our Assay and Modeling platform bridges the gap between genotypic edits and phenotypic outcomes. By experimentally characterizing key cellular metrics (Assays) and using this data to parameterize predictive Models, we can accurately simulate the effects of genetic modifications before they are built in the lab. This is crucial for controlling energy supply, folding capacity, and the host's native glycosylation profile. This integrated approach allows our clients to prioritize the most effective genetic targets (e.g., in the folding pathway or stress response genes) and drastically reduce the development timeline.
Metabolomics & Fluxomics
GC-MS/LC-MS analysis of central carbon metabolism and amino acid consumption, including ${}^{13}\text{C}$ tracing, to quantify flux distribution (e.g., energy supply) and identify metabolic limitations during the post-infection phase.
Proteomics & Secretomics
Quantification of ER chaperone expression (e.g., BiP, PDI) and analysis of the host secretome (HCPs) and product stability, linking folding capacity to productivity.
Glycan & PTM Analysis
High-resolution analysis of N- and O-glycan profiles, charge variants, and aggregation states, providing essential feedback for glycoengineering efforts.
Constraint-Based Metabolic Modeling (CBM)
Utilization of the insect cell genome-scale model to predict maximum theoretical yields, optimize nutrient feeding, and propose effective gene modifications (KO/KI) to enhance energy and precursor supply.
Dynamic Kinetic Modeling
Development of dynamic models to simulate time-dependent changes in cell viability, viral load, and substrate consumption post-infection, optimizing MOI and harvest time (TPI).
Glycosylation Pathway Modeling
Specialized models simulating the flux through the host's (and heterologous human) N-glycosylation pathway based on enzyme expression and nucleotide sugar availability to predict product glycoprofiles.
Optimal Target Recommendation
Using model outputs (e.g., CBM/Kinetic) to recommend the most impactful genetic targets for knockout (e.g., proteases, native glycoenzymes), or Base Editing (e.g., chaperone tuning).
Bioprocess Strategy Prediction
Simulating the effect of culture conditions (temperature, pH) and feeding rates on viral replication and protein production dynamics, optimizing industrial protocols.
Folding Bottleneck Identification
Integrating proteomics data with model predictions to pinpoint limitations in the ER/Golgi folding machinery, guiding targeted overexpression or tuning strategies.
We connect high-quality experimental data with predictive simulation to deliver highly efficient strain optimization.
1. Initial Modeling & Target Identification
2. Experimental Cell Culture & Sampling
3. Quantitative Data Assays
4. Model Validation & Refinement
Establish a compartmentalized CBM and Dynamic Kinetic Model based on the Sf9/BEVS system and target protein.
Simulate effects of potential edits (KO/KI/tuning) and predict optimal MOI/TPI.
Generate initial hypothesis on bottlenecks (e.g., nucleotide sugar limits, folding stress, lytic cycle timing).
Cultivate wild-type and initially engineered Sf9 Cell lines under highly controlled lab-scale bioreactor conditions (e.g., shaker flasks, DASbox).
Infect with rBV and collect samples (cells and supernatant) at specific TPI points reflecting expression dynamics.
Integrate new experimental assay data to validate and refine the computational model parameters.
Identify prediction errors, extract new design rules specific to BEVS infection dynamics and host PTMs, and recommend the final optimization strategy (e.g., Multi-gene KO of proteases).
Delivery of the predictive model and data-driven optimization strategy.
BEVS Dynamic Control
Dynamic Kinetic Modeling simulates the time-dependent viral infection process, allowing for the precise optimization of infection parameters (MOI, TPI) and feeding schedules to maximize yield.
Integrated Glycoengineering
Models the complex relationship between host metabolism (nucleotide sugar pools) and product glycoprofiles, essential for humanizing insect cell-derived biotherapeutics.
Folding & Secretion Analysis
Proteomics and fluxomics assays map the capacity and limitations of the ER/Golgi folding and secretion machinery under high viral/expression load, guiding targeted host factor tuning.
Data-Driven Rational Design
Assay data (Fluxomics, Glycan analysis) is used to directly parameterize the CBM, ensuring every subsequent genetic edit (KO/KI/BE) is based on quantitative, empirical cellular data.
1. How does modeling help optimize the MOI and TPI for production?
Dynamic Kinetic Modeling simulates the progression of the lytic cycle and corresponding protein production rates, predicting the optimal Multiplicity of Infection (MOI) and Time Post-Infection (TPI) to harvest for maximal product yield before cell lysis.
2. How is the undesirable $\alpha(1,3)$-fucose minimized through modeling?
The model is used to simulate the effect of knocking out the native fucosyltransferase enzyme and inserting the human pathway, ensuring the cellular environment (nucleotide sugar pools) can support the humanized glycan structure.
3. What is the role of Fluxomics in Sf9 optimization?
Fluxomics quantifies the carbon and nitrogen flow during high-demand phases (post-infection). This identifies bottlenecks in energy (ATP) generation and precursor supply, guiding genetic engineering to enhance pathway capacity.
4. Can the model predict protein folding efficiency?
While folding itself is complex, the model integrates proteomics data on ER chaperone levels (e.g., BiP) and PDI expression with energy demands to predict folding stress. This guides the tuning of host factors to maximize soluble product yield.
5. How does the model help extend the productive window post-infection?
The model simulates cell death pathways in response to viral stress, predicting the effect of tuning anti-apoptosis genes (CRISPRi/BE). This allows for targeted engineering to extend cell viability during the late, high-production phase.
6. What experimental input is required to build a model for an Sf9 Cell line?
Model building requires data on viral kinetics, nutrient uptake/excretion rates, $\text{Q}_\text{p}$ pre- and post-infection, metabolomics, and proteomics/glycan profiles of the specific cell line (Sf9/Hi5) under production conditions.
7. What type of output recommendations are provided?
We provide a prioritized list of actionable targets, including specific KO targets (proteases, native glycoenzymes), Base Editing sites for promoter/chaperone tuning, and optimal bioprocess parameters (MOI, TPI, feeding strategy).
8. How do you ensure the stability of pathway modifications?
All permanent modifications (KO/KI) are integrated into the insect cell chromosome via CRISPR/HDR, ensuring the modified traits are genetically stable and passed on reliably to all progeny, independent of the transient viral vector.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.